1. Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis
   Yangyun Huang et al, 2021, Human Vaccines & Immunotherapeutics CrossRef
2. Lung cancer with spontaneous regression of primary and metastatic sites: A case report
   RYOKO OGAWA et al, 2015, Oncology Letters CrossRef
3. Radiation Therapy for Metastatic Lung Cancer: Liver Metastasis
   Fiori Alite et al, 2022, Advances in Radiation Oncology in Lung Cancer CrossRef
4. Parotid metastases from primary lung cancer: Case series and systematic review of the features
   Rulan Wang et al, 2022, Frontiers in Oncology CrossRef
5. The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment
   Francesca Pontis et al, 2023, Frontiers in Oncology CrossRef
6. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data
   Jinqi He et al, 2021, Mathematical Biosciences and Engineering CrossRef
7. The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer
   E. McDermott et al, 2021, Abdominal Radiology CrossRef
8. Analysis of bevacizumab treatments and metastatic sites of lung cancer
   Hideomi Sato et al, 2021, Cancer Treatment and Research Communications CrossRef
9. Hyperattenuating adrenal lesions in lung cancer: biphasic CT with unenhanced and 1-min enhanced images reliably predicts benign lesions
   Ho Yun Lee et al, 2021, European Radiology CrossRef
10. Case report: Acute pancreatitis in lung adenocarcinoma with small cell transformation after multiple line targeted therapy
    Yaoyao Jing et al, 2024, Frontiers in Oncology CrossRef
11. PATTERN OF LUNG CANCER METASTASIS BASED ON PET CT
    Harsha D.S et al, 2017, Journal of Evidence Based Medicine and Healthcare CrossRef
12. Integrative bioinformatics analysis reveals ECM and nicotine-related genes in both LUAD and LUSC, but different lung fibrosis-related genes are involved in LUAD and LUSC
    Marzyeh Alipour et al, 2024, Nucleosides, Nucleotides & Nucleic Acids CrossRef
13. Metastasis of pulmonary adenocarcinoma to the oral cavity: A case report and literatures review of the last 30 years
    Masami Kawaharada et al, 2022, Oral Science International CrossRef
14. Metastatic sites and survival in lung cancer
    M. Riihimäki et al, 2014, Lung Cancer CrossRef
15. From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC
    Maria Protopapa et al, 2019, Journal of Oncology CrossRef
16. The Role of the ECM in Lung Cancer Dormancy and Outgrowth
    Amelia L. Parker et al, 2020, Frontiers in Oncology CrossRef
17. Metastatic Disease of the Lung
    Z. Hammoud et al, 2022, Cancer Metastasis Through the Lymphovascular System CrossRef
18. Sites of Synchronous Distant Metastases, Prognosis, and Nomogram for Small Cell Lung Cancer Patients with Bone Metastasis: A Large Cohort Retrospective Study
    Zhiyi Fan et al, 2021, Journal of Oncology CrossRef
19. Modeling and predicting the occurrence of brain metastasis from lung cancer by Bayesian network: A case study of Taiwan
    Kung-Jeng Wang et al, 2014, Computers in Biology and Medicine CrossRef
20. Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer
    T. Duell et al, 2015, Cancer Treatment Communications CrossRef
21. Impact of different patterns of metastasis in non-small-cell lung cancer patients
    Larissy Machado da Silva et al, 2021, Future Oncology CrossRef
22. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
    Handai Xia et al, 2022, Frontiers in Oncology CrossRef
23. How to scan who: the delicate balance between selecting the patient and selecting the imaging protocol
    Roland Hustinx, 2017, European Journal of Nuclear Medicine and Molecular Imaging CrossRef
24. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
    Yuki Takeyasu et al, 2021, Clinical Lung Cancer CrossRef